Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN H STRICKLER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1265523377
CMS profile
598917
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$69,997.83

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN H STRICKLER

NPI 1265523377 · CMS profile ID 598917

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN H STRICKLER, NPI 1265523377, CMS profile ID 598917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOHN H STRICKLER, NPI 1265523377, CMS profile ID 598917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOHN H STRICKLER, NPI 1265523377, CMS profile ID 598917, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $69,997.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–56 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $143.0002/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204429204 CMS
ABBVIE INC. $247.4702/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204429209 CMS
TAIHO ONCOLOGY, INC. $1,560.0002/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211406556 CMS
Janssen Research & Development, LLC $60.2102/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1173801679 CMS
PFIZER INC. $118.0801/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228946256 CMS
TAIHO ONCOLOGY, INC. $164.0001/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211410526 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,972.12 13
PY2020 $25,484.89 22
PY2021 $20,725.87 9
PY2022 $34,474.02 30
PY2023 $61,930.71 39
PY2024 $97,529.43 87
PY2025 $69,997.83 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,509.76 3
PY2025 Principal investigator $4,058,488.29 589
PY2024 Recipient $10,108.75 6
PY2024 Principal investigator $5,722,468.05 524
PY2023 Recipient $869.51 6
PY2023 Principal investigator $4,654,510.51 265
PY2022 Principal investigator $1,919,878.43 77
PY2021 Recipient $1,012.50 1
PY2021 Principal investigator $3,398,972.39 80
PY2020 Principal investigator $2,192,265.69 49
PY2019 Principal investigator $1,276,540.75 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

592 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $550.00 12/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab No dispute reported 06/30/2026 1202534333
Principal investigator 1 ABBVIE INC. $3,617.27 12/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202535191
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE (DCI) - DUKE CANCER CENTER
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination with Bevacizumab in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202535193
Principal investigator 1 BeOne Medicines USA, Inc. $3,888.00 12/30/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190329917
Principal investigator 1 Daiichi Sankyo Inc. $208.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367621
Principal investigator 1 Daiichi Sankyo Inc. $68.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367623
Principal investigator 1 Daiichi Sankyo Inc. $169.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367625
Principal investigator 1 Daiichi Sankyo Inc. $45.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367627
Principal investigator 1 Daiichi Sankyo Inc. $68.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367629
Principal investigator 1 Daiichi Sankyo Inc. $57.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367631
Principal investigator 1 Daiichi Sankyo Inc. $226.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367633
Principal investigator 1 Daiichi Sankyo Inc. $117.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367635
Principal investigator 1 Daiichi Sankyo Inc. $537.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367639
Principal investigator 1 Daiichi Sankyo Inc. $86.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367641
Principal investigator 1 Daiichi Sankyo Inc. $226.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367643
Principal investigator 1 Daiichi Sankyo Inc. $2,598.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367645
Principal investigator 1 Daiichi Sankyo Inc. $666.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367647
Principal investigator 1 Daiichi Sankyo Inc. $25.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367649
Principal investigator 1 Daiichi Sankyo Inc. $72.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367653
Principal investigator 1 Daiichi Sankyo Inc. $4,825.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367655
Principal investigator 1 Daiichi Sankyo Inc. $86.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367657
Principal investigator 1 Daiichi Sankyo Inc. $366.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367659
Principal investigator 1 Daiichi Sankyo Inc. $460.00 12/18/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367661
Principal investigator 1 Roche Products Limited $3,284.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598909
Principal investigator 1 Roche Products Limited $3,223.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598913
Principal investigator 1 Roche Products Limited $5,178.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598916
Principal investigator 1 Roche Products Limited $4,640.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598920
Principal investigator 1 Roche Products Limited $3,917.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598925
Principal investigator 1 Roche Products Limited $1,345.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598929
Principal investigator 1 Roche Products Limited $10,679.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598933
Principal investigator 1 Roche Products Limited $3,003.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598940
Principal investigator 1 Roche Products Limited $3,636.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598950
Principal investigator 1 Roche Products Limited $2,713.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598958
Principal investigator 1 Roche Products Limited $5,353.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598969
Principal investigator 1 Roche Products Limited $8,250.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598973
Principal investigator 1 Roche Products Limited $4,640.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598978
Principal investigator 1 Roche Products Limited $2,128.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598981
Principal investigator 1 Roche Products Limited $3,758.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598985
Principal investigator 1 Roche Products Limited $2,857.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598989
Principal investigator 1 Roche Products Limited $4,640.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211599002
Principal investigator 1 Roche Products Limited $1,250.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211599007
Principal investigator 1 Roche Products Limited $3,758.00 12/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211599011
Principal investigator 1 Genentech, Inc. $9,355.00 12/15/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211598660
Principal investigator 1 Roche Products Limited $820.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598900
Principal investigator 1 Roche Products Limited $422.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598905
Principal investigator 1 Roche Products Limited $2,393.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598935
Principal investigator 1 Roche Products Limited $5,110.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598946
Principal investigator 1 Roche Products Limited $5,731.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598955
Principal investigator 1 Roche Products Limited $1,122.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598962
Principal investigator 1 Roche Products Limited $880.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598966
Principal investigator 1 Roche Products Limited $5,242.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598993
Principal investigator 1 Roche Products Limited $2,459.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598998
Principal investigator 1 Roche Products Limited $414.00 12/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211599015
Principal investigator 1 Genentech, Inc. $1,380.00 12/08/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211598656
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 12/03/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367637
Principal investigator 1 PFIZER INC. $4,124.58 11/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228729443
Recipient ABBVIE INC. $1,812.00 11/20/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202401583
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192174421
Principal investigator 1 GlaxoSmithKline, LLC. $3,325.00 11/17/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192174434
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523931
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523933
Principal investigator 1 ABBVIE INC. $1,702.40 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523935
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523937
Principal investigator 1 ABBVIE INC. $2,447.20 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523939
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523949
Principal investigator 1 ABBVIE INC. $248.71 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523953
Principal investigator 1 ABBVIE INC. $250.00 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523955
Principal investigator 1 ABBVIE INC. $250.00 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523959
Principal investigator 1 ABBVIE INC. $1,702.40 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523969
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523971
Principal investigator 1 ABBVIE INC. $248.71 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523973
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523975
Principal investigator 1 ABBVIE INC. $1,000.00 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523977
Principal investigator 1 ABBVIE INC. $1,702.40 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523979
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523981
Principal investigator 1 ABBVIE INC. $250.00 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523983
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523985
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523987
Principal investigator 1 ABBVIE INC. $250.00 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523989
Principal investigator 1 ABBVIE INC. $250.00 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523991
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523993
Principal investigator 1 ABBVIE INC. $611.80 11/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202523995
Principal investigator 1 ABBVIE INC. $27,728.43 11/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan No dispute reported 06/30/2026 1202521889
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 11/05/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367619
Principal investigator 1 ABBVIE INC. $7,182.00 11/04/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202520391
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518979
Principal investigator 1 ABBVIE INC. $2,649.36 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518981
Principal investigator 1 ABBVIE INC. $3,040.38 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518983
Principal investigator 1 ABBVIE INC. $2,649.36 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518985
Principal investigator 1 ABBVIE INC. $3,733.31 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518989
Principal investigator 1 ABBVIE INC. $3,733.31 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518991
Principal investigator 1 ABBVIE INC. $2,036.23 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519007
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519009
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519019
Principal investigator 1 ABBVIE INC. $3,733.31 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519055
Principal investigator 1 ABBVIE INC. $3,040.38 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519065
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519071
Principal investigator 1 ABBVIE INC. $2,036.23 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519089
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519121
Principal investigator 1 ABBVIE INC. $3,040.38 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519123
Principal investigator 1 ABBVIE INC. $2,649.36 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519125
Principal investigator 1 ABBVIE INC. $2,036.23 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519127
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519129
Principal investigator 1 ABBVIE INC. $3,733.31 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519143
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519149
Principal investigator 1 ABBVIE INC. $3,733.31 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519151
Principal investigator 1 ABBVIE INC. $2,649.36 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519157
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519159
Principal investigator 1 ABBVIE INC. $2,036.23 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519161
Principal investigator 1 ABBVIE INC. $3,066.98 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519185
Principal investigator 1 ABBVIE INC. $3,040.38 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519187
Principal investigator 1 ABBVIE INC. $3,040.38 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519203
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519219
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519259
Principal investigator 1 ABBVIE INC. $3,040.38 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519261
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519265
Principal investigator 1 ABBVIE INC. $3,653.51 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519267
Principal investigator 1 ABBVIE INC. $2,649.36 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519327
Principal investigator 1 ABBVIE INC. $6,927.97 10/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519515
Principal investigator 1 GlaxoSmithKline, LLC. $2,128.00 10/28/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113096
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 10/28/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113115
Principal investigator 1 GlaxoSmithKline, LLC. $2,211.76 10/28/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113134
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 10/28/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192174429
Principal investigator 1 ABBVIE INC. $53.20 10/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518553
Principal investigator 1 ABBVIE INC. $884.45 10/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518555
Principal investigator 1 ABBVIE INC. $3,914.19 10/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518569
Principal investigator 1 ABBVIE INC. $3,914.19 10/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518571
Principal investigator 1 ABBVIE INC. $3,914.19 10/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518573
Principal investigator 1 ABBVIE INC. $500.08 10/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518575
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112925
Principal investigator 1 GlaxoSmithKline, LLC. $226.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112932
Principal investigator 1 GlaxoSmithKline, LLC. $460.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113085
Principal investigator 1 GlaxoSmithKline, LLC. $3,325.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113108
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113164
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113180
Principal investigator 1 GlaxoSmithKline, LLC. $460.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168364
Principal investigator 1 GlaxoSmithKline, LLC. $226.00 10/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168373
Principal investigator 1 ABBVIE INC. $409.64 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517723
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517737
Principal investigator 1 ABBVIE INC. $1,013.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517739
Principal investigator 1 ABBVIE INC. $1,013.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517741
Principal investigator 1 ABBVIE INC. $444.22 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517743
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517753
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517755
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517757
Principal investigator 1 ABBVIE INC. $65.17 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517759
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517761
Principal investigator 1 ABBVIE INC. $1,013.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517791
Principal investigator 1 ABBVIE INC. $409.64 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517795
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517797
Principal investigator 1 ABBVIE INC. $595.84 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517799
Principal investigator 1 ABBVIE INC. $148.96 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517801
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517803
Principal investigator 1 ABBVIE INC. $65.17 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517805
Principal investigator 1 ABBVIE INC. $223.44 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517807
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517821
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517823
Principal investigator 1 ABBVIE INC. $444.22 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517825
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517829
Principal investigator 1 ABBVIE INC. $1,013.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517831
Principal investigator 1 ABBVIE INC. $65.17 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517833
Principal investigator 1 ABBVIE INC. $148.96 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517855
Principal investigator 1 ABBVIE INC. $747.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517857
Principal investigator 1 ABBVIE INC. $65.17 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517859
Principal investigator 1 ABBVIE INC. $747.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517861
Principal investigator 1 ABBVIE INC. $171.57 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517863
Principal investigator 1 ABBVIE INC. $444.22 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517865
Principal investigator 1 ABBVIE INC. $148.96 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517867
Principal investigator 1 ABBVIE INC. $223.44 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517869
Principal investigator 1 ABBVIE INC. $115.71 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517871
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517873
Principal investigator 1 ABBVIE INC. $409.64 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517875
Principal investigator 1 ABBVIE INC. $4,765.39 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517877
Principal investigator 1 ABBVIE INC. $409.64 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517879
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517881
Principal investigator 1 ABBVIE INC. $11,461.94 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517883
Principal investigator 1 ABBVIE INC. $409.64 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517897
Principal investigator 1 ABBVIE INC. $11,461.94 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517899
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517901
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517903
Principal investigator 1 ABBVIE INC. $444.22 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517905
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517907
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517909
Principal investigator 1 ABBVIE INC. $2,616.11 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517911
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517913
Principal investigator 1 ABBVIE INC. $409.64 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517915
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517933
Principal investigator 1 ABBVIE INC. $2,242.38 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517935
Principal investigator 1 ABBVIE INC. $5,730.97 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517937
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517939
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517941
Principal investigator 1 ABBVIE INC. $1,494.92 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517943
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517945
Principal investigator 1 ABBVIE INC. $11,461.94 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517947
Principal investigator 1 ABBVIE INC. $11,461.94 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517949
Principal investigator 1 ABBVIE INC. $444.22 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517951
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517953
Principal investigator 1 ABBVIE INC. $297.92 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517955
Principal investigator 1 ABBVIE INC. $115.71 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517957
Principal investigator 1 ABBVIE INC. $747.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517959
Principal investigator 1 ABBVIE INC. $5,730.97 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517961
Principal investigator 1 ABBVIE INC. $1,013.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517963
Principal investigator 1 ABBVIE INC. $1,121.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517965
Principal investigator 1 ABBVIE INC. $373.73 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517967
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517969
Principal investigator 1 ABBVIE INC. $11,461.94 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517971
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517977
Principal investigator 1 ABBVIE INC. $595.84 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517979
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517981
Principal investigator 1 ABBVIE INC. $1,013.46 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517983
Principal investigator 1 ABBVIE INC. $223.44 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517985
Principal investigator 1 ABBVIE INC. $171.57 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517993
Principal investigator 1 ABBVIE INC. $115.71 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517995
Principal investigator 1 ABBVIE INC. $11,461.94 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517997
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518001
Principal investigator 1 ABBVIE INC. $506.73 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518003
Principal investigator 1 ABBVIE INC. $11,461.94 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518005
Principal investigator 1 ABBVIE INC. $409.64 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518007
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518037
Principal investigator 1 ABBVIE INC. $2,622.76 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518039
Principal investigator 1 ABBVIE INC. $506.73 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518041
Principal investigator 1 ABBVIE INC. $57.19 10/22/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518043
Recipient Amgen Inc. $429.01 10/20/2025 Covered Recipient Physician A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigators Choice (Trifluridine and Tipiracil or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation No dispute reported 06/30/2026 1246636908
Principal investigator 1 ABBVIE INC. $3,617.27 10/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202513457
Principal investigator 1 PFIZER INC. $4,124.58 10/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228730520
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 10/02/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367651
Principal investigator 1 BeOne Medicines USA, Inc. $4,595.00 09/30/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190328579
Principal investigator 1 ABBVIE INC. $1,094.59 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512616
Principal investigator 1 ABBVIE INC. $6,927.97 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512648
Principal investigator 1 ABBVIE INC. $6,927.97 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512650
Principal investigator 1 ABBVIE INC. $2,501.22 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512656
Principal investigator 1 ABBVIE INC. $2,501.22 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512658
Principal investigator 1 ABBVIE INC. $3,747.94 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512672
Principal investigator 1 ABBVIE INC. $6,927.97 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512674
Principal investigator 1 ABBVIE INC. $6,927.97 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512694
Principal investigator 1 ABBVIE INC. $6,927.97 09/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512704
Principal investigator 1 ABBVIE INC. $994.84 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512454
Principal investigator 1 ABBVIE INC. $460.00 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512456
Principal investigator 1 ABBVIE INC. $3,258.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512460
Principal investigator 1 ABBVIE INC. $332.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512462
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512464
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512466
Principal investigator 1 ABBVIE INC. $332.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512470
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512472
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512474
Principal investigator 1 ABBVIE INC. $332.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512476
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512478
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512480
Principal investigator 1 ABBVIE INC. $332.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512484
Principal investigator 1 ABBVIE INC. $332.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512486
Principal investigator 1 ABBVIE INC. $3,258.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512488
Principal investigator 1 ABBVIE INC. $3,258.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512490
Principal investigator 1 ABBVIE INC. $332.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512492
Principal investigator 1 ABBVIE INC. $332.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512494
Principal investigator 1 ABBVIE INC. $3,258.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512496
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512504
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512506
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512508
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512510
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512512
Principal investigator 1 ABBVIE INC. $3,258.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512514
Principal investigator 1 ABBVIE INC. $2,984.52 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512516
Principal investigator 1 ABBVIE INC. $2,210.00 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512518
Principal investigator 1 ABBVIE INC. $3,258.50 09/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512520
Principal investigator 1 ABBVIE INC. $248.71 09/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512048
Principal investigator 1 ABBVIE INC. $248.71 09/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512050
Principal investigator 1 ABBVIE INC. $1,731.99 09/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512078
Principal investigator 1 PFIZER INC. $32,997.51 09/22/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718339
Principal investigator 1 PFIZER INC. $10,940.00 09/22/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228718341
Principal investigator 1 PFIZER INC. $10,940.00 09/19/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716899
Principal investigator 1 PFIZER INC. $32,997.51 09/19/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716971
Principal investigator 1 GlaxoSmithKline, LLC. $2,081.58 09/18/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113090
Principal investigator 1 GlaxoSmithKline, LLC. $2,445.17 09/18/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113188
Principal investigator 1 BeOne Medicines USA, Inc. $6,375.00 09/09/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190328583
Principal investigator 1 ABBVIE INC. $2,971.22 09/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202508074
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 09/03/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367609
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 09/03/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367611
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 09/03/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367613
Principal investigator 1 ABBVIE INC. $2,491.09 09/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506767
Principal investigator 1 ABBVIE INC. $2,036.23 08/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503679
Principal investigator 1 ABBVIE INC. $2,036.23 08/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503681
Principal investigator 1 ABBVIE INC. $2,036.23 08/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202503691
Principal investigator 1 ABBVIE INC. $1,556.10 08/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202501694
Principal investigator 1 ABBVIE INC. $4,040.50 08/04/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202500928
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 08/01/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367615
Principal investigator 1 BeOne Medicines USA, Inc. $8,555.00 07/29/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190328581
Principal investigator 1 ABBVIE INC. $3,747.94 07/28/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202500002
Principal investigator 1 GlaxoSmithKline, LLC. $6,755.87 07/21/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113174
Principal investigator 1 ABBVIE INC. $5,745.60 07/08/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202497144
Principal investigator 1 Merck Sharp & Dohme LLC $118,200.00 07/03/2025 Non-covered Recipient Entity
Duke University
A Phase 1,2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction GEJ, or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and,or the ChecKpoint Inhibitor Pembrolizumab. TWINPEAK Study No dispute reported 06/30/2026 1232936160
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 07/02/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367617
Principal investigator 1 BeOne Medicines USA, Inc. $99,521.00 07/01/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190332663
Principal investigator 1 ABBVIE INC. $3,368.89 06/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493481
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493039
Principal investigator 1 ABBVIE INC. $2,501.22 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493041
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493043
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493047
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493049
Principal investigator 1 ABBVIE INC. $1,352.61 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493051
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493053
Principal investigator 1 ABBVIE INC. $2,501.22 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493055
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493057
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493059
Principal investigator 1 ABBVIE INC. $1,352.61 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493061
Principal investigator 1 ABBVIE INC. $3,747.94 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493063
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493065
Principal investigator 1 ABBVIE INC. $3,747.94 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493067
Principal investigator 1 ABBVIE INC. $2,501.22 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493069
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493071
Principal investigator 1 ABBVIE INC. $3,747.94 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493073
Principal investigator 1 ABBVIE INC. $884.45 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493089
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493091
Principal investigator 1 ABBVIE INC. $2,501.22 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493093
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493115
Principal investigator 1 ABBVIE INC. $884.45 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493117
Principal investigator 1 ABBVIE INC. $3,747.94 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493119
Principal investigator 1 ABBVIE INC. $551.95 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493121
Principal investigator 1 ABBVIE INC. $2,501.22 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493123
Principal investigator 1 ABBVIE INC. $1,246.72 06/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493137
Principal investigator 1 Daiichi Sankyo Inc. $834.11 06/24/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367765
Principal investigator 1 Daiichi Sankyo Inc. $5,685.71 06/24/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367767
Principal investigator 1 ABBVIE INC. $4,473.54 06/20/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492529
Principal investigator 1 BeOne Medicines Ltd. $17,993.00 06/17/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190330999
Principal investigator 1 PFIZER INC. $2,394.00 06/16/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS No dispute reported 06/30/2026 1228793140
Principal investigator 1 GlaxoSmithKline, LLC. $4,565.36 06/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192174439
Principal investigator 1 PFIZER INC. $6,252.50 06/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228778296
Principal investigator 1 Daiichi Sankyo Inc. $22,167.60 06/05/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367763
Principal investigator 1 Daiichi Sankyo Inc. $1,202.32 06/05/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367769
Principal investigator 1 ABBVIE INC. $8,877.75 06/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202488551
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 06/02/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367605
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 06/02/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367607
Principal investigator 1 TAIHO ONCOLOGY, INC. $74,964.25 05/31/2025 Covered Recipient Teaching Hospital
Duke University Hospital
Expansion of the Duke Molecular Tumor Board to community oncology sites across theSoutheast to support adoption of comprehensive genomic profiling and biomarker driventherapy selection for lung and thyroid cancer patients No dispute reported 06/30/2026 1211415095
Principal investigator 1 BeOne Medicines Ltd. $14,006.00 05/30/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190330997
Principal investigator 1 BeOne Medicines Ltd. $2,976.00 05/30/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331459
Principal investigator 1 Eli Lilly and Company $247,981.69 05/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1A/1B TRIAL OF LY3962673 IN PARTICIPANTS WITH KRAS G12D-MUTANT SOLID TUMORS No dispute reported 06/30/2026 1187881378
Principal investigator 1 Genentech, Inc. $3,450.00 05/28/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211598651
Principal investigator 1 ABBVIE INC. $1,954.77 05/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202486271
Principal investigator 1 ABBVIE INC. $1,954.77 05/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202486273
Principal investigator 1 ABBVIE INC. $3,000.00 05/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202486275
Principal investigator 1 ABBVIE INC. $1,954.77 05/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202486277
Principal investigator 1 Genentech, Inc. $2,445.00 05/23/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
1L Biliary Tract Cancer No dispute reported 06/30/2026 1211598664
Principal investigator 1 Daiichi Sankyo Inc. $22,858.16 05/22/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367761
Principal investigator 1 Genentech, Inc. $446.07 05/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
1L Biliary Tract Cancer No dispute reported 06/30/2026 1211598313
Principal investigator 1 Eli Lilly and Company $74,102.38 05/15/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS No dispute reported 06/30/2026 1187879873
Principal investigator 1 BeiGene, Ltd. $56,092.00 05/09/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190324006
Principal investigator 1 Genentech, Inc. $2,870.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598458
Principal investigator 1 Genentech, Inc. $1,345.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598462
Principal investigator 1 Genentech, Inc. $10,679.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598466
Principal investigator 1 Genentech, Inc. $8,250.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598470
Principal investigator 1 Genentech, Inc. $3,758.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598474
Principal investigator 1 Genentech, Inc. $2,857.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598478
Principal investigator 1 Genentech, Inc. $4,640.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598482
Principal investigator 1 Genentech, Inc. $1,345.00 05/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598486
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480083
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480085
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480087
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480099
Principal investigator 1 ABBVIE INC. $551.95 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480101
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480103
Principal investigator 1 ABBVIE INC. $3,653.51 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480105
Principal investigator 1 ABBVIE INC. $4,072.46 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480107
Principal investigator 1 ABBVIE INC. $6,927.97 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480109
Principal investigator 1 ABBVIE INC. $3,922.17 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480111
Principal investigator 1 ABBVIE INC. $6,344.10 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480113
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480123
Principal investigator 1 ABBVIE INC. $3,733.31 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480125
Principal investigator 1 ABBVIE INC. $3,653.51 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480127
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480133
Principal investigator 1 ABBVIE INC. $3,653.51 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480135
Principal investigator 1 ABBVIE INC. $4,482.10 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480137
Principal investigator 1 ABBVIE INC. $2,036.23 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480143
Principal investigator 1 ABBVIE INC. $3,733.31 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480145
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480147
Principal investigator 1 ABBVIE INC. $3,653.51 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480149
Principal investigator 1 ABBVIE INC. $3,653.51 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480151
Principal investigator 1 ABBVIE INC. $762.09 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480157
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480159
Principal investigator 1 ABBVIE INC. $1,094.59 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480161
Principal investigator 1 ABBVIE INC. $884.45 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480163
Principal investigator 1 ABBVIE INC. $6,344.10 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480165
Principal investigator 1 ABBVIE INC. $2,649.36 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480167
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480181
Principal investigator 1 ABBVIE INC. $3,733.31 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480183
Principal investigator 1 ABBVIE INC. $4,482.10 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480185
Principal investigator 1 ABBVIE INC. $2,036.23 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480187
Principal investigator 1 ABBVIE INC. $884.45 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480391
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480393
Principal investigator 1 ABBVIE INC. $2,501.22 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480397
Principal investigator 1 ABBVIE INC. $2,036.23 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480399
Principal investigator 1 ABBVIE INC. $2,491.09 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480401
Principal investigator 1 ABBVIE INC. $4,072.46 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480403
Principal investigator 1 ABBVIE INC. $3,040.38 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480411
Principal investigator 1 ABBVIE INC. $3,040.38 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480413
Principal investigator 1 ABBVIE INC. $3,314.36 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480415
Principal investigator 1 ABBVIE INC. $3,314.36 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480417
Principal investigator 1 ABBVIE INC. $3,314.36 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480419
Principal investigator 1 ABBVIE INC. $4,072.46 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480421
Principal investigator 1 ABBVIE INC. $2,649.36 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480429
Principal investigator 1 ABBVIE INC. $4,482.10 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480431
Principal investigator 1 ABBVIE INC. $3,040.38 04/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480433
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 04/25/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367601
Principal investigator 1 Amgen Inc. $44,623.45 04/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) No dispute reported 06/30/2026 1246640967
Principal investigator 1 BeiGene, Ltd. $18,601.00 04/21/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190324008
Principal investigator 1 PFIZER INC. $10,940.00 04/16/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228755010
Principal investigator 1 PFIZER INC. $10,940.00 04/15/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228756295
Recipient ABBVIE INC. $1,268.75 04/14/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202401579
Principal investigator 1 PFIZER INC. $16,810.74 04/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228792009
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 04/02/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367603
Principal investigator 1 ABBVIE INC. $1,834.07 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467341
Principal investigator 1 ABBVIE INC. $2,327.50 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467345
Principal investigator 1 ABBVIE INC. $1,292.76 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467349
Principal investigator 1 ABBVIE INC. $3,767.89 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467353
Principal investigator 1 ABBVIE INC. $2,501.22 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467357
Principal investigator 1 ABBVIE INC. $4,822.58 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467360
Principal investigator 1 ABBVIE INC. $1,121.19 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467365
Principal investigator 1 ABBVIE INC. $2,501.22 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467368
Principal investigator 1 ABBVIE INC. $2,380.70 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467429
Principal investigator 1 ABBVIE INC. $2,327.50 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467433
Principal investigator 1 ABBVIE INC. $2,501.22 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467437
Principal investigator 1 ABBVIE INC. $1,121.19 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467442
Principal investigator 1 ABBVIE INC. $2,501.22 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467619
Principal investigator 1 ABBVIE INC. $1,318.03 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467623
Principal investigator 1 ABBVIE INC. $2,501.22 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467640
Principal investigator 1 ABBVIE INC. $2,327.50 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467643
Principal investigator 1 ABBVIE INC. $1,352.61 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467677
Principal investigator 1 ABBVIE INC. $1,352.61 03/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467681
Principal investigator 1 ABBVIE INC. $4,282.60 03/25/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465962
Principal investigator 1 ABBVIE INC. $497.42 03/25/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465974
Principal investigator 1 ABBVIE INC. $250.00 03/25/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202466056
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465557
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465561
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465565
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465569
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465573
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465577
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465580
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465584
Principal investigator 1 ABBVIE INC. $13.30 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465588
Principal investigator 1 ABBVIE INC. $176.89 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465618
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465633
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465638
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465642
Principal investigator 1 ABBVIE INC. $1,246.72 03/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465646
Principal investigator 1 BeiGene, Ltd. $14,180.00 03/24/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190324002
Principal investigator 1 Genentech, Inc. $1,279.23 03/20/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211598309
Principal investigator 1 ABBVIE INC. $920.00 03/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202464409
Principal investigator 1 ABBVIE INC. $248.71 03/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202464413
Principal investigator 1 ABBVIE INC. $3,710.00 03/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202464417
Principal investigator 1 Daiichi Sankyo Inc. $12,069.56 03/13/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367751
Principal investigator 1 Daiichi Sankyo Inc. $4,695.00 03/13/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367755
Principal investigator 1 BeiGene, Ltd. $55,740.00 03/10/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190324004
Principal investigator 1 PFIZER INC. $7,350.00 03/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS No dispute reported 06/30/2026 1228787697
Principal investigator 1 PFIZER INC. $13,500.00 03/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS No dispute reported 06/30/2026 1228795449
Principal investigator 1 GlaxoSmithKline, LLC. $1,330.00 03/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113128
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 03/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113140
Principal investigator 1 GlaxoSmithKline, LLC. $7,182.00 03/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113168
Principal investigator 1 GlaxoSmithKline, LLC. $4,788.00 03/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168360
Principal investigator 1 GlaxoSmithKline, LLC. $7,448.00 03/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168383
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 03/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168387
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 03/07/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192174443
Principal investigator 1 ABBVIE INC. $53.20 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458936
Principal investigator 1 ABBVIE INC. $82.46 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458939
Principal investigator 1 ABBVIE INC. $481.46 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458943
Principal investigator 1 ABBVIE INC. $180.88 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458948
Principal investigator 1 ABBVIE INC. $406.98 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458960
Principal investigator 1 ABBVIE INC. $46.55 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458963
Principal investigator 1 ABBVIE INC. $481.46 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458971
Principal investigator 1 ABBVIE INC. $239.40 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458974
Principal investigator 1 ABBVIE INC. $166.25 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458979
Principal investigator 1 ABBVIE INC. $59.85 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458981
Principal investigator 1 ABBVIE INC. $66.50 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202458985
Principal investigator 1 ABBVIE INC. $2,451.19 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455994
Principal investigator 1 ABBVIE INC. $4,482.10 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455998
Principal investigator 1 ABBVIE INC. $6,927.97 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456009
Principal investigator 1 ABBVIE INC. $2,447.20 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456013
Principal investigator 1 ABBVIE INC. $6,927.97 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456063
Principal investigator 1 ABBVIE INC. $2,984.52 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456156
Principal investigator 1 ABBVIE INC. $1,596.00 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456159
Principal investigator 1 ABBVIE INC. $4,072.46 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456163
Principal investigator 1 ABBVIE INC. $6,927.97 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456168
Principal investigator 1 ABBVIE INC. $2,491.09 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456171
Principal investigator 1 ABBVIE INC. $4,482.10 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456175
Principal investigator 1 ABBVIE INC. $4,072.46 03/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202456179
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 03/05/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367593
Principal investigator 1 PFIZER INC. $520.00 03/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS No dispute reported 06/30/2026 1228795436
Principal investigator 1 Roche Products Limited $1,500.00 03/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598534
Principal investigator 1 Roche Products Limited $678.00 03/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598544
Principal investigator 1 Roche Products Limited $3,325.00 03/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598567
Principal investigator 1 ABBVIE INC. $10,687.00 02/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M24-311 - Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202454397
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112915
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112921
Principal investigator 1 GlaxoSmithKline, LLC. $226.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112938
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112943
Principal investigator 1 GlaxoSmithKline, LLC. $226.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112949
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112954
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192112960
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113103
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113122
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113147
Principal investigator 1 GlaxoSmithKline, LLC. $226.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113152
Principal investigator 1 GlaxoSmithKline, LLC. $226.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192113158
Principal investigator 1 GlaxoSmithKline, LLC. $226.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168368
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168376
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192174425
Principal investigator 1 GlaxoSmithKline, LLC. $2,713.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192174448
Principal investigator 1 Roche Products Limited $1,345.00 02/24/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598584
Principal investigator 1 Daiichi Sankyo Inc. $2,798.56 02/20/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367753
Principal investigator 1 Daiichi Sankyo Inc. $5,645.24 02/20/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367757
Principal investigator 1 Daiichi Sankyo Inc. $3,897.09 02/20/2025 Non-covered Recipient Entity
Duke University
DS8201-A-U207 No dispute reported 06/30/2026 1223367759
Principal investigator 1 PFIZER INC. $31,493.56 02/18/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228796887
Principal investigator 1 PFIZER INC. $7,500.00 02/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS No dispute reported 06/30/2026 1228793787
Principal investigator 1 PFIZER INC. $260.00 02/10/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS No dispute reported 06/30/2026 1228795961
Principal investigator 1 ABBVIE INC. $1,500.00 02/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202446492
Principal investigator 1 ABBVIE INC. $750.00 02/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202446507
Principal investigator 1 ABBVIE INC. $4,894.40 02/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202446511
Principal investigator 1 ABBVIE INC. $960.00 02/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202446515
Principal investigator 1 PFIZER INC. $32,997.51 02/04/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228755013
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 02/03/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367595
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 02/03/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367599
Principal investigator 1 PFIZER INC. $32,997.51 02/03/2025 Non-covered Recipient Entity
Duke Cancer Center
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228756757
Principal investigator 1 ABBVIE INC. $3,840.00 01/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443258
Principal investigator 1 ABBVIE INC. $460.00 01/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443312
Principal investigator 1 ABBVIE INC. $5,000.00 01/30/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202443321
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442056
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442060
Principal investigator 1 ABBVIE INC. $1,218.28 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442064
Principal investigator 1 ABBVIE INC. $762.09 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442096
Principal investigator 1 ABBVIE INC. $1,820.77 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442100
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442104
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442109
Principal investigator 1 ABBVIE INC. $1,218.28 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442407
Principal investigator 1 ABBVIE INC. $884.45 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442410
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442413
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442417
Principal investigator 1 ABBVIE INC. $4,072.46 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442442
Principal investigator 1 ABBVIE INC. $2,036.23 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442446
Principal investigator 1 ABBVIE INC. $960.00 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442636
Principal investigator 1 ABBVIE INC. $3,571.05 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442727
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442730
Principal investigator 1 ABBVIE INC. $3,571.05 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442749
Principal investigator 1 ABBVIE INC. $3,747.94 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442753
Principal investigator 1 ABBVIE INC. $1,094.59 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442757
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442761
Principal investigator 1 ABBVIE INC. $6,344.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442765
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442769
Principal investigator 1 ABBVIE INC. $3,653.51 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442773
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442776
Principal investigator 1 ABBVIE INC. $884.45 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442779
Principal investigator 1 ABBVIE INC. $6,927.97 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442783
Principal investigator 1 ABBVIE INC. $1,602.65 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442786
Principal investigator 1 ABBVIE INC. $884.45 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442790
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442795
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442799
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442815
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442819
Principal investigator 1 ABBVIE INC. $3,747.94 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442823
Principal investigator 1 ABBVIE INC. $1,218.28 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442826
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442830
Principal investigator 1 ABBVIE INC. $762.09 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442833
Principal investigator 1 ABBVIE INC. $3,584.35 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442837
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442846
Principal investigator 1 ABBVIE INC. $1,218.28 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442850
Principal investigator 1 ABBVIE INC. $3,922.17 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442854
Principal investigator 1 ABBVIE INC. $2,649.36 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442859
Principal investigator 1 ABBVIE INC. $3,584.35 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442864
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442867
Principal investigator 1 ABBVIE INC. $551.95 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442871
Principal investigator 1 ABBVIE INC. $551.95 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442876
Principal investigator 1 ABBVIE INC. $2,501.22 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442889
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442893
Principal investigator 1 ABBVIE INC. $1,250.00 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442896
Principal investigator 1 ABBVIE INC. $551.95 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442900
Principal investigator 1 ABBVIE INC. $884.45 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442905
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442909
Principal investigator 1 ABBVIE INC. $4,482.10 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442913
Principal investigator 1 Amgen Inc. $240,898.77 01/29/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100) No dispute reported 06/30/2026 1246640929
Principal investigator 1 BeiGene, Ltd. $4,878.00 01/21/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190324888
Principal investigator 1 BeiGene, Ltd. $7,354.00 01/21/2025 Non-covered Recipient Entity
Duke University ,
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190324890
Principal investigator 1 ABBVIE INC. $24,478.43 01/15/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202438617
Principal investigator 1 Amgen Inc. $806,134.89 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) No dispute reported 06/30/2026 1246640935
Principal investigator 1 Daiichi Sankyo Inc. $2,218.00 01/03/2025 Non-covered Recipient Entity
Duke University
ROMAST-001 No dispute reported 06/30/2026 1223367597
Principal investigator 1 Roche Products Limited $1,345.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598531
Principal investigator 1 Roche Products Limited $4,353.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598539
Principal investigator 1 Roche Products Limited $4,788.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598549
Principal investigator 1 Roche Products Limited $14,630.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598553
Principal investigator 1 Roche Products Limited $5,178.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598557
Principal investigator 1 Roche Products Limited $399.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598562
Principal investigator 1 Roche Products Limited $3,000.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598571
Principal investigator 1 Roche Products Limited $1,110.55 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598575
Principal investigator 1 Roche Products Limited $8,250.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598581
Principal investigator 1 Roche Products Limited $904.00 01/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
EiH study with WRNinh in MSI dMMR advanced solid tumors No dispute reported 06/30/2026 1211598588
Principal investigator 1 Amgen Inc. $419,511.88 01/02/2025 Non-covered Recipient Entity
DUKE CANCER CENTER
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) No dispute reported 06/30/2026 1246640897